This article is more than 5 years old. Information may no longer be current.

MacuCLEAR, Mystic Pharmaceuticals enter agreement for trial of AMD drop

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

PLANO, Texas — MacuCLEAR has entered into a collaboration agreement with Mystic Pharmaceuticals to conduct a phase 1/2 clinical trial of its lead compound for treating age-related macular degeneration, according to a press release from MacuCLEAR, the developer of the drug.

The trial will evaluate the effects of the compound, called MC1101, when delivered topically through Mystic's novel unit dose drug delivery platform, called VersiDoser.

"We believe Mystic's novel VersiDoser delivery system will help overcome many of the challenges of topical delivery of ophthalmic drugs to the eye," Philip G. Ralston Jr., president and chief executive officer of MacuCLEAR, said in the release. "Standard eyedroppers typically deliver too large a drop that 'floods' the eye. Conventional eyedroppers waste product and are difficult for elderly patients to use reliably on a daily basis. Mystic's individually packaged drops can be precisely sized and accurately delivered with a unique dispenser that is easy to use."